Bronte Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Bronte Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-578,313	Closed	-$3.44M	–	33
2022 Q2	$3.44M	Hold	578,313	–	–	0.39%	26
2022 Q1	$3.66M	Buy	578,313 +40,729	+8%	+$229K	0.31%	25
2021 Q4	$2.1M	Sell	537,584 -11,252	-2%	-$48.8K	0.14%	26
2021 Q3	$2.65M	Hold	548,836	–	–	0.19%	24
2021 Q2	$3.51M	Sell	548,836 -1,843	-0.3%	-$12.2K	0.25%	19
2021 Q1	$3.46M	Buy	550,679 +19,169	+4%	+$137K	0.39%	17
2020 Q4	$3.66M	Hold	531,510	–	–	0.58%	15
2020 Q3	$2.05M	Buy	+531,510	New	+$1.95M	0.36%	13

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Bronte Capital Management's MACK Position: Q3 2022 in Review

Bronte Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2022, closing a stake of 578,313 shares — an estimated $3.44M sold.

Bronte Capital Management first reported a position in MACK in Q3 2020 and held it in 8 quarters. The position peaked at $3.66M in Q4 2020. 41 funds tracked by Wall St. Rank hold MACK as of Q3 2022.

Bronte Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Bronte Capital Management sold 578,313 Merrimack Pharmaceuticals, Inc. shares in Q3 2022, an estimated $3.44M.
Bronte Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2020 and held it in 8 quarters.
Bronte Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $3.66M in Q4 2020.
41 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2022.

Based on Bronte Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.